drugset / Trial / NCT02530034
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Phase 1
Active not recruiting
72 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.
Timeline
- Start
- 2019-01-31
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hu8F4 | Monoclonal antibody | — | Intravenous |